EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune Control, HBsAg Loss or Flare Requiring Liver Transplant—Diverse Outcomes After Stopping NUC Therapy

Katarina Lund, Miriam Frankal iD, Anders Eilard, Joakim Bedner Stenbäck iD, Erik Alestig, Arno Furquim d'Almeida iD, Staffan Nilsson, Thomas Vanwolleghem iD, Johan Westin iD, Johan Ringlander iD, Gustaf E Rydell iD, Magnus Lindh iD

Viruses · 2026

DOI: 10.3390/v18091026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2026. Verfasst von Katarina Lund und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Norra Älvsborg's Hospital, 461 73 Trollhättan, Sweden. Hauptthemen laut MEDLINE: Liver Transplantation, Hepatitis B Surface Antigens, Hepatitis B, Chronic, Antiviral Agents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Cancer Society, Government of Sweden, FWO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis B surface antigen (HBsAg) loss is rarely achieved during long-term nucleos(t)ide analogue (NUC) therapy of chronic hepatitis B. Treatment discontinuation may lead to immune activation and HBsAg loss. In a prospective study, HBeAg-negative patients without liver cirrhosis stopped NUC therapy after a duration of at least 3 years. Follow-up for 2 years comprised monthly monitoring for the first six months. Twenty-five patients who discontinued therapy and six randomized controls who continued were included. After stopping NUC therapy, five patients (20%) developed an HBsAg seroclearance pattern, including four who lost HBsAg and one who achieved HBsAg below 1 IU/mL. Seven patients (28%) developed a state of immune control with persistently low HBV DNA and normal ALT. Six patients (24%) experienced severe flares requiring NUC re-initiation; all of them, including one with fulminant hepatitis necessitating liver transplantation, had detectable hepatitis B core-related antigen (HBcrAg) in serum at NUC discontinuation. The peak serum HBV DNA level strongly correlated with and preceded peak ALT. Thus, although half of the patients had favorable outcomes, there was a substantial risk of severe flares preceded by HBV DNA levels above 6 log10 IU/mL. Close monitoring, including frequent HBV DNA testing with rapid turnaround time, is therefore essential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationHepatitis B Surface AntigensHepatitis B, ChronicAntiviral AgentsHumansFemaleDNA, ViralHepatitis B virusMaleAdultProspective StudiesMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

HBV DNAHBsAgchronic hepatitis Bfollow-uphepatitis B virusliver transplantationprospective study

Substanzen

Hepatitis B Surface AntigensAntiviral AgentsDNA, Viral

Autor:innen und Institutionen

  • Department of Infectious Diseases, Norra Älvsborg's Hospital, 461 73 Trollhättan, Sweden.
  • Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden.
  • Department of Infectious Diseases, Södra Älvsborg's Hospital, 501 82 Borås, Sweden.
  • Department of Infectious Diseases, Sahlgrenska University Hospital, 413 46 Gothenburg, Sweden.
  • Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, 2610 Antwerp, Belgium.
  • Department of Gastroenterology and Hepatology, Antwerp University Hospital, 2650 Antwerp, Belgium.

ORCID-Profile: Miriam Frankal, Joakim Bedner Stenbäck, Arno Furquim d'Almeida, Thomas Vanwolleghem, Johan Westin, Johan Ringlander, Gustaf E Rydell, Magnus Lindh

Förderung

  • Swedish Cancer Society
  • Government of Sweden
  • FWO

Zitieren

APA

Lund, K., Frankal, M., Eilard, A., Bedner Stenbäck, J., Alestig, E., Furquim d'Almeida, A., Nilsson, S., Vanwolleghem, T., Westin, J., Ringlander, J., Rydell, G. E., & Lindh, M. (2026). Immune Control, HBsAg Loss or Flare Requiring Liver Transplant—Diverse Outcomes After Stopping NUC Therapy. Viruses. https://doi.org/10.3390/v18091026

Vancouver

Lund K, Frankal M, Eilard A, Bedner Stenbäck J, Alestig E, Furquim d'Almeida A, et al. Immune Control, HBsAg Loss or Flare Requiring Liver Transplant—Diverse Outcomes After Stopping NUC Therapy. Viruses. 2026. doi:10.3390/v18091026

BibTeX
@article{Lund2026,
  author = {Lund, Katarina and Frankal, Miriam and Eilard, Anders and Bedner Stenbäck, Joakim and Alestig, Erik and Furquim d'Almeida, Arno and Nilsson, Staffan and Vanwolleghem, Thomas and Westin, Johan and Ringlander, Johan and Rydell, Gustaf E and Lindh, Magnus},
  title = {Immune Control, HBsAg Loss or Flare Requiring Liver Transplant—Diverse Outcomes After Stopping NUC Therapy},
  journal = {Viruses},
  year = {2026},
  doi = {10.3390/v18091026}
}
Kostenlos starten →